LRIG2 and cancer: Moreover, the absence of any obvious morphogenetic or gross cochlear patterning defects argues against the idea that Lrig1 and Lrig2 act redundantly to control any of the major signaling pathways, consistent with their distinct effects in vitro and in cancer.